^
    1d
    VAG-3+7-G: VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML (clinicaltrials.gov)
    P3, N=300, Not yet recruiting, Institute of Hematology & Blood Diseases Hospital, China | Initiation date: Jan 2026 --> Apr 2026
    Trial initiation date
    |
    FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2)
    |
    FLT3-ITD mutation • FLT3-TKD mutation
    |
    Venclexta (venetoclax) • cytarabine • Xospata (gilteritinib) • azacitidine • daunorubicin • idarubicin hydrochloride
    3d
    Fruquintinib Plus Checkpoint Inhibitor Combined or Sequential TAS-102 in Colorectal Cancer Patients Who Progressed on Second-line Standard Therapy: a Prospective, Multi-cohort, Single-centered, Phase Ib/II Study (clinicaltrials.gov)
    P1/2, N=106, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P1/2 trial • Checkpoint inhibition
    |
    MSI (Microsatellite instability) • MLH1 (MutL homolog 1) • MSH6 (MutS homolog 6) • MSH2 (MutS Homolog 2)
    |
    Avastin (bevacizumab) • Fruzaqla (fruquintinib) • Lonsurf (trifluridine/tipiracil)
    4d
    Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Sun Yat-sen University
    New P2 trial • IO biomarker
    |
    Fruzaqla (fruquintinib) • Hetronifly (serplulimab)
    9d
    Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (clinicaltrials.gov)
    P2, N=42, Active, not recruiting, Chipscreen Biosciences, Ltd. | Recruiting --> Active, not recruiting | Trial completion date: Jul 2026 --> Oct 2026 | Trial primary completion date: Feb 2026 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    gemcitabine • albumin-bound paclitaxel • Auraza (chiauranib)
    14d
    OSU-23199: SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation (clinicaltrials.gov)
    P1, N=30, Recruiting, Uma Borate | Trial completion date: Dec 2025 --> Feb 2027 | Trial primary completion date: Dec 2025 --> Jan 2027
    Trial completion date • Trial primary completion date
    |
    FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • NUP98 (Nucleoporin 98 And 96 Precursor 2) • MEIS1 (Meis Homeobox 1)
    |
    FLT3 mutation • NPM1 mutation • MLL mutation
    |
    Xospata (gilteritinib) • Revuforj (revumenib)
    14d
    Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • oxaliplatin • irinotecan • Sulanda (surufatinib)
    15d
    Ultrasound-triggered dissolving microneedle platform for cGAS-STING-mediated precision immunotherapy of melanoma. (PubMed, Mater Today Bio)
    Herein, we reported an ultrasound (US)-controllable all-in-one dissolving microneedle (dMN) platform that integrated a ROS-cleavable prodrug, formed by conjugating the VEGF inhibitor linifanib, with ROS-responsive liposomes encapsulating the sonosensitizer MnTCPP (Mn@CTL-LPs dMNs)...This spatiotemporally controllable activation ensured high therapeutic precision and safety. Overall, this work presented a noninvasive and US-triggered strategy to potentiate sonodynamic immunotherapy for melanoma.
    Journal
    |
    CD8 (cluster of differentiation 8) • STING (stimulator of interferon response cGAMP interactor 1)
    |
    linifanib (ABT-869)
    15d
    Explore the efficacy of microwave ablation combined with fruquintinib and tislelizumab in the treatment of metastatic colorectal cancer. (PubMed, Front Oncol)
    It is anticipated that these findings will expand therapeutic options available to patients. https://www.chictr.org.cn/showproj.html?proj=140822, identifier ChiCTR 2200058323 (China Clinical Trial Center).
    Journal
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Tevimbra (tislelizumab-jsgr) • Fruzaqla (fruquintinib)
    17d
    Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=29, Completed, Sun Yat-sen University | Recruiting --> Completed | Trial completion date: Aug 2025 --> Jan 2026
    Trial completion • Trial completion date • Platinum resistant
    |
    Partruvix (pamiparib) • Sulanda (surufatinib)
    17d
    Pan-cancer analysis of NTRK2 (TRKB) and the anticancer effect of its inhibitor Lucitanib in glioma. (PubMed, Comput Biol Chem)
    Its efficacy was intermediate between methotrexate and the selective NTRK2 inhibitor ana-12. Mechanistically, Lucitanib targeted the NTRK2-AKT-MMP9 axis while preserving immune effector functions. These findings establish NTRK2 as a viable therapeutic target in gliomas and highlight Lucitanib as a novel multi-mechanistic inhibitor with balanced efficacy and favorable pharmacokinetic properties, supporting its further development for clinical translation in NTRK2-overexpressing gliomas.
    Journal • IO biomarker • Pan tumor
    |
    BCL2 (B-cell CLL/lymphoma 2) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MMP9 (Matrix metallopeptidase 9)
    |
    methotrexate • lucitanib (E 3810)
    18d
    Connective tissue growth factor contributes to resistance to anti-angiogenic therapies in renal cancer. (PubMed, Theranostics)
    Clear cell renal cell carcinoma (ccRCC) is predominantly treated with anti-angiogenic therapies (AATs), such as sunitinib and axitinib. CTGF may thus serve as both a predictive biomarker and a therapeutic target. These findings support further investigation of CTGF inhibition as a strategy to overcome AAT resistance and improve treatment outcomes in ccRCC patients.
    Journal
    |
    CTGF (Connective tissue growth factor)
    |
    sunitinib • axitinib
    20d
    A Multifunctional Calcium Phosphate Nanoplatform Inducing Synergistic Copper/Calcium Overload and Antiangiogenesis for Enhanced Cancer Therapy. (PubMed, ACS Nano)
    Here, we develop a multifunctional nanoplatform (CaP/Cu-F) by incorporating L-buthionine sulfoximine (BSO) into copper-doped calcium phosphate nanoparticles, followed by the loading of fruquintinib, a vascular endothelial growth factor receptor (VEGFR) inhibitor...By integrating redox modulation, calcium overload, cuproptosis, and antiangiogenesis, the CaP/Cu-F nanoplatform exhibits potent antitumor and antimetastatic efficacy. This work thus presents a promising strategy for synergistic cancer therapy.
    Journal
    |
    ATP7A (ATPase Copper Transporting Alpha) • DLAT (Dihydrolipoamide S-Acetyltransferase)
    |
    Fruzaqla (fruquintinib)